Acambis plc is a developer of vaccines against infectious diseases. In its smallpox vaccine franchise, the Company has two investigational products, ACAM2000 and Modified Vaccinia Ankara (MVA), and also acts as agent for sales of a third investigational product, Vaccinia Immune Globulin (VIG), for Cangene Corporation outside North America and Israel. As a result of the Berna Products Corporation (BPC) acquisition in August 2003, Acambis is developing a travel vaccine franchise and has a number of vaccines undergoing clinical testing that it plans to channel through BPC alongside Vivotif, including vaccines against yellow fever and Japanese encephalitis. A vaccine against dengue fever is being developed in collaboration with Aventis Pasteur. In November 2003, Acambis initiated human clinical trials of a vaccine against the West Nile virus. Initial data from this trial was reported in May 2004.